Drugs / autologous nucleated cord blood cells
autologous nucleated cord blood cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02612155 | Mar 2017 → Aug 2019 | perinatal asphyxia | Michael Cotten | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous nucleated cord blood cells | “infants with moderate to severe hypoxic ischemic encephalopathy, begin cooling, and have autologous nucleated cord blood cells available for infusion will receive up to two infusions.” NCT02612155 ↗ |
| Modality | Cell therapy | “autologous nucleated cord blood cells available for infusion” NCT02612155 ↗ |
| Route | Intravenous | “up to two intravenous infusions” NCT02612155 ↗ |